In The News

Oct 7, 2026 Empowered Patient Podcast: Reprogramming Cancer Biology to Overcome Treatment Resistance with Dr. John Friend, Kazia Therapeutics

Sep 30, 2026 Rx for Biotech Podcast: How Cancer Uses an 'Invisibility Cloak' - And How Kazia Therapeutics Is Trying to Remove It

Sep 25, 2026 CURE: How Paxalisib Is Being Studied in Treatment-Resistant Breast Cancer

Sep 24, 2026 Authority Magazine: Female Disruptors: Sudha Rao of Kazia Therapeutics On The Three Things You Need To Shake Up Your Industry

Sep 23, 2026 BioPharma APAC: Sovargen Doses First Patient in Phase Ib/IIa Trial of Kazia’s Paxalisib for Rare Epilepsies

Sep 22, 2026 CURE: Paxalisib Trial Expands to HR-Positive, HER2-Negative Breast Cancer

Sep 22, 2026 CURE: How Paxalisib Targets Treatment Resistance in Breast Cancer

Sep 14, 2026 Discover Pharma: Kazia Reports 83% ResponseRrate for Paxalisib in Triple-Negative Breast Cancer

Sep 11, 2026 BioPharma APAC: Kazia Doses First Patient in Phase II Study of Paxalisib Combination for Aggressive Paediatric Brain Cancer

Sep 9, 2026 MedPath Trial: Kazia Therapeutics Doses First Patient in PNOC035 Phase 2 Trial of Paxalisib Plus Gemcitabine for Recurrent Pediatric AT/RT

Sep 9, 2026 Cancer Network: Paxalisib/Gemcitabine Combination Dosed in First Patient With CNS Tumor

Sep 4, 2026 GenomeWeb: Kazia Therapeutics to Start Paxalisib Phase II Colorectal Cancer Trial

Select a page